Reviewing XOMA Royalty (NASDAQ:XOMA) & Enzon Pharmaceuticals (OTCMKTS:ENZN)

Enzon Pharmaceuticals (OTCMKTS:ENZN) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for Enzon Pharmaceuticals and XOMA Royalty, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enzon Pharmaceuticals	0	0	0	0	0.00
XOMA Royalty	1	2	3	0	2.33

XOMA Royalty has a consensus target price of $61.60, indicating a potential upside of 114.56%. Given XOMA Royalty’s stronger consensus rating and higher possible upside, analysts plainly believe XOMA Royalty is more favorable than Enzon Pharmaceuticals.

Institutional & Insider Ownership

95.9% of XOMA Royalty shares are held by institutional investors. 0.4% of Enzon Pharmaceuticals shares are held by company insiders. Comparatively, 9.1% of XOMA Royalty shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Enzon Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, XOMA Royalty has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Profitability

This table compares Enzon Pharmaceuticals and XOMA Royalty’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enzon Pharmaceuticals	N/A	-263.18%	-10.11%
XOMA Royalty	45.75%	10.32%	3.49%

Valuation and Earnings

This table compares Enzon Pharmaceuticals and XOMA Royalty”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enzon Pharmaceuticals	$30,000.00	148.43	-$3.41 million	($0.07)	-0.86
XOMA Royalty	$52.15 million	6.56	-$13.82 million	$0.74	38.80

Enzon Pharmaceuticals has higher earnings, but lower revenue than XOMA Royalty. Enzon Pharmaceuticals is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Summary

XOMA Royalty beats Enzon Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.